Mariola Dymkowska is a pivotal figure at VERTO MD, where she leverages her extensive expertise in immunology-oncology and targeted therapies to drive innovative clinical development initiatives. With a focus on newly identified pathways, rare diseases, and niche indications, Mariola is at the forefront of advancing...
Mariola Dymkowska is a pivotal figure at VERTO MD, where she leverages her extensive expertise in immunology-oncology and targeted therapies to drive innovative clinical development initiatives. With a focus on newly identified pathways, rare diseases, and niche indications, Mariola is at the forefront of advancing therapeutic strategies in hematology-oncology, particularly concerning leukemia and lymphoma. Her role encompasses a comprehensive approach to clinical development, medical affairs, and pharmacovigilance, ensuring that cutting-edge therapies are not only developed but also delivered safely and effectively to patients across diverse regions.
Currently, Mariola is spearheading several key projects aimed at exploring first-in-human trials and optimizing clinical protocols that address unmet medical needs in both established and emerging markets. Her direct experience in the pharmaceutical industry spans multiple geographic regions, including the European Union (EU), Central and Eastern Europe (CEE), the Middle East, Turkey, Africa (META), South Asia, Australia (APAC), Russia, and even extending to Latin America (LATAM) and China. This broad operational scope allows her to navigate complex regulatory landscapes and foster collaborations that enhance the reach and impact of innovative therapies.
Mariola's strategic planning capabilities, combined with her deep understanding of pharmacovigilance and medical affairs, position her as a leader in the field. She is committed to ensuring that the development of new therapies is accompanied by rigorous safety monitoring and compliance with international standards. Through her work at VERTO MD, Mariola Dymkowska is not only contributing to the advancement of hematology-oncology but is also shaping the future of targeted therapies for rare diseases, ultimately improving patient outcomes on a global scale.
